EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary
acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.